Drug Trials Snapshot: HYRNUO - HYRNUO (sevabertinib)

https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-hyrnuo HYRNUO is a tyrosine-kinase inhibitor that is indicated for the treatment of adult patients with non-squamous non-small cell lung cancer (NSCLC) caused by abnormal HER2 (ERBB2) gene mutation in the tyrosine kinase domain (TKD) that is locally advanced or has spread to other parts of the body (metastatic), and who have received a prior systemic therapy.